PatientsVille.com LogoPatientsVille.com

Pleural Neoplasms | The ISET (Isolation by Size of Epithelial Tumor Cells) and the CellSearch Methods in Malignant Pleural Mesothelioma

Pleural Neoplasms research study

What is the primary objective of this study?

Malignant pleural mesothelioma (MPM) has a growing incidence and in spite of early diagnostic, their outcome remains dismal. The evolution of MPM is often local with rare distant metastases. There is now a sizable body of evidence that metastases could develop from circulating tumor cells (CTC) spread in blood before or during surgery. Thus, sensitive and specific detection of CTC in blood is considered as a potentially relevant predictive biomarker for patients with carcinomas. In exchange, the prognostic value of CTC in MPM has not yet been evaluated. Indeed, the main goal for preoperative detection of CTC is to identify patients with high risk of recurrence after surgery, in order to perform more adapted therapeutic strategy. Despite several studies reported about CTC detection, methodological aspects concerning sensitivity, specificity and reproducibility have prevented a clear appraisal of their clinical impact. Thus, the aim of our study is to evaluate the presence and the prognostic value of CTC in MPM by a double approach. In our setting, cytopathological analysis of circulating non hematological cells (CNHC), of epithelial origin, isolated according to their size (ISET, Isolation by Size of Epithelial Tumor cells) along with immunomagnetic selection, identification and enumeration of circulating epithelial cells in peripheral blood (CellSearch method) is considered a promising approach.

Who is eligible to participate?

Inclusion Criteria For the patients: - Age > 18 years - Patient having been operated for a strong suspicion of a pleural malignant tumoral lesion corresponding to a primitive pleural mesothelioma - Signed patient consent For the control subjects: - Age > 18 years - unhurt of any malignant or mild tumoral pathology or patients that must benefit from a surgical procedure for a benign lesion in other organ than the pleura or a pulmonary non tumoral lesion - Signed patient consent Exclusion Criteria : - Patient with histories of cancer or the other synchronous cancer - Patient with additives treatments - Patient according to treatments additives others than protocols codified (in particular, platinum navelbine or gemcitabine platinum) for stages II - HIV, hepatitis B or C infections - Pregnant women

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Pleural Neoplasms

Mesothelioma

Pneumothorax

Parathyroid Neoplasms

Benign Tumor of the Thyroid

Tumor of the Thyroid

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Other:Blood samplingBiological: ISET and CellSearch Methods Sampling of blood - ISET and CellSearch Methods

Other:Control GroupBiological: ISET and CellSearch Methods Sampling of blood - ISET and CellSearch Methods

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

Group patientsPatients with Malignant Pleural Mesothelioma (all stages)

Control groupPatients with pneumothorax or of benign tumor of the thyroid

Study Status

Completed

Start Date: February 2012

Completed Date: March 2018

Phase: N/A

Type: Interventional

Design:

Primary Outcome: Evaluation of presence / absence of CTC on the global survival

Secondary Outcome: Value forecasts of the number of CTC on the global survival estimated by the risk

Study sponsors, principal investigator, and references

Principal Investigator: ILIE Marius, PhD

Lead Sponsor: Centre Hospitalier Universitaire de Nice

Collaborator:

More information:https://clinicaltrials.gov/show/NCT01776385

Discuss Pneumothorax